NUVL 📈 Nuvalent - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6707031075
NUVL: Cancer, Therapies, Inhibitors, Lung Cancer, Brain Metastases, Tumors
Nuvalent, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for cancer patients. The company's lead product candidates are designed to address specific clinical challenges associated with existing treatments, such as emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases. For instance, NVL-520 is a novel ROS1-selective inhibitor that aims to overcome the limitations of current ROS1 tyrosine kinase inhibitors (TKIs) used to treat ROS1-positive non-small cell lung cancer (NSCLC). This candidate is currently in the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial, which is evaluating its safety and efficacy in patients with this specific type of cancer.
Another key product candidate in Nuvalent's pipeline is NVL-655, a brain-penetrant ALK-selective inhibitor. This therapy is being developed to address the clinical challenges associated with first-, second-, and third-generation ALK inhibitors, which can be limited by emergent treatment resistance, CNS-related adverse events, and brain metastases. The ALKOVE-1 Phase 1/2 clinical trial is currently ongoing, with the phase 2 portion assessing the safety and efficacy of NVL-655 in patients with ALK-positive cancer. Additionally, Nuvalent is working on NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor, which is designed to treat tumors driven by HER2ex20 and brain metastases, while minimizing treatment-limiting adverse events due to off-target inhibition of wild-type EGFR.
Nuvalent's approach to cancer therapy is centered on developing targeted treatments that can effectively penetrate the brain and address the complex challenges associated with cancer metastases. By focusing on specific molecular targets, such as ROS1, ALK, and HER2, the company aims to create therapies that can provide meaningful benefits to patients with limited treatment options. With its headquarters in Cambridge, Massachusetts, Nuvalent is well-positioned to leverage the region's rich biotechnology ecosystem and collaborate with leading research institutions to advance its pipeline of innovative cancer therapies.
As a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol NUVL, Nuvalent is committed to transparency and accountability in its operations. The company's common stock is traded under the ISIN code US6707031075, and it is classified under the GICS Sub Industry: Biotechnology. For more information about Nuvalent and its pipeline of cancer therapies, investors and stakeholders can visit the company's website at https://www.nuvalent.com.
Additional Sources for NUVL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NUVL Stock Overview
Market Cap in USD | 5,740m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2021-07-29 |
NUVL Stock Ratings
Growth 5y | 77.7% |
Fundamental | -6.80% |
Dividend | - |
Rel. Strength Industry | 815 |
Analysts | 4.5/5 |
Fair Price Momentum | 81.38 USD |
Fair Price DCF | - |
NUVL Dividends
No Dividends PaidNUVL Growth Ratios
Growth Correlation 3m | -73.9% |
Growth Correlation 12m | 55.6% |
Growth Correlation 5y | 89% |
CAGR 5y | 51.23% |
CAGR/Mean DD 5y | 1.91 |
Sharpe Ratio 12m | 0.26 |
Alpha | -32.87 |
Beta | 1.63 |
Volatility | 44.70% |
Current Volume | 342.2k |
Average Volume 20d | 533.7k |
As of January 09, 2025, the stock is trading at USD 78.25 with a total of 342,160 shares traded.
Over the past week, the price has changed by -2.18%, over one month by -16.68%, over three months by -23.58% and over the past year by +7.49%.
Neither. Based on ValueRay Fundamental Analyses, Nuvalent is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -6.80 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NUVL as of January 2025 is 81.38. This means that NUVL is currently overvalued and has a potential downside of 4%.
Nuvalent has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy NUVL.
- Strong Buy: 8
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, NUVL Nuvalent will be worth about 91.4 in January 2026. The stock is currently trading at 78.25. This means that the stock has a potential upside of +16.82%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 115.1 | 47.1% |
Analysts Target Price | 115.1 | 47.1% |
ValueRay Target Price | 91.4 | 16.8% |